# Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer

> **NCT04210037** · PHASE1,PHASE2 · TERMINATED · sponsor: **Ascentage Pharma Group Inc.** · enrollment: 28 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** APG-1252
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT04210037
- **Lead sponsor:** Ascentage Pharma Group Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-20
- **Primary completion:** 2021-08-30
- **Final completion:** 2022-05-15
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2022-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04210037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04210037, "Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT04210037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*